Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
about
Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policiesPharmaceutical policies: effects of reference pricing, other pricing, and purchasing policiesThe new medicare drug benefit: formularies and their potential effects on access to medicationsFirst-line first? Trends in thiazide prescribing for hypertensive seniorsThe impact of cost sharing on antidepressant use among older adults in British Columbia.Comparison of tiered formularies and reference pricing policies: a systematic review.Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants.Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarctionEffects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications.Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications.Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data.Effectiveness, safety and cost of drug substitution in hypertensionPatient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription dataAre incentive-based formularies inversely associated with drug utilization in managed care?Drug insurance utilization management policies and "reference pricing": an illustrated commentary on the article by Vittorio Maio and colleagues.Measuring prescribing improvements in pragmatic trials of educational tools for general practitioners.The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbiaThe effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.The impact of reference-pricing systems in Europe: a literature review and case studies.Impact of rosiglitazone meta-analysis on use of glucose-lowering medications.Does knowledge of medication prices predict physicians' support for cost effective prescribing policies.Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians?
P2860
Q24193097-B19F9E08-805F-4887-B1AF-5BE7E0585D57Q24246148-F12352B9-3B83-479B-89E5-2F09194CDA7CQ24540426-DEB65F09-17E7-4635-91D6-714C01B2944AQ24792251-F83129CE-94D1-4831-B6EA-2BA80BDD26B2Q33908092-DC425DB8-B44E-48AE-8FE8-A0FBAA38143FQ33908282-F18DE316-5278-466C-AA02-BE8862277525Q33942027-0BC46398-1FA3-468C-A180-F739410D1086Q34001855-EBBF3ECC-2506-49C6-8206-BA005FEE4FC0Q34001878-05F87DD4-72FD-4E8A-B9E6-EB218902F66AQ34001895-E9C96338-20FE-4A67-BF78-652FD7C83ED0Q34090275-A0D0FEE3-823A-47D4-876E-6A990ED1F8A8Q34174844-85D84EAD-E4F4-4344-8BFE-A59A6BBF92E0Q34199300-AD599296-B99F-42A9-A6A3-AA4A39B112E2Q36006232-9A2BA7A0-6A61-4F13-865D-EEA3709AEDBBQ36078789-0AB0D907-71DB-45E7-AAE8-FF335E45789CQ36447520-6366E585-E060-4E26-8F04-D912A5DF0933Q37103226-D2147E44-7295-4C55-B1D7-F4D72BC2FA67Q37420464-CD015F10-D719-47CB-952D-4FDCFADC3BD8Q37958057-D5FFEBC0-7D3D-4C87-8EEA-0A2DD5964B03Q41807349-41E35145-2AAB-433C-AB90-28BB08BA1E78Q42612841-D05C7FB6-D7F6-47AD-A291-CB6512E4CA8BQ43167477-13B089EA-D2E1-4D81-BABF-0F6B7CD93C43
P2860
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Clinical and economic conseque ...... dine calcium channel blockers.
@en
Clinical and economic conseque ...... dine calcium channel blockers.
@nl
type
label
Clinical and economic conseque ...... dine calcium channel blockers.
@en
Clinical and economic conseque ...... dine calcium channel blockers.
@nl
prefLabel
Clinical and economic conseque ...... dine calcium channel blockers.
@en
Clinical and economic conseque ...... dine calcium channel blockers.
@nl
P2093
P1476
Clinical and economic conseque ...... dine calcium channel blockers.
@en
P2093
Alexander M Walker
Malcolm Maclure
Robert J Glynn
Sebastian Schneeweiss
Stephen B Soumerai
P304
P356
10.1016/S0009-9236(03)00227-3
P407
P577
2003-10-01T00:00:00Z